纤维蛋白原浓缩物对高危心脏手术术中出血患者术中失血量的影响:一项随机临床试验
在荷兰Isala Zwolle开展的一项随机、安慰剂对照、双盲临床试验,纳入120例高危心脏手术术中出血患者,随机接受单剂纤维蛋白原浓缩物或安慰剂,目标使输注后血浆纤维蛋白原达2.5 g/L。结果显示纤维蛋白原组术中失血量中位数50 mL与对照组70 mL相比无显著差异(P=0.19)。
要点
- 在高危心脏手术术中出血患者中,纤维蛋白原浓缩物与安慰剂相比术中失血量无显著差异。
- 纤维蛋白原组失血量中位数50 mL,对照组70 mL,绝对差异20 mL(95%CI -13至35 mL),P=0.19。
- 两组安全性事件包括卒中或短暂性脑缺血发作、心肌梗死、死亡、肾功能不全或衰竭及再次开胸等情况。
核心结论
- 在高危心脏手术术中出血患者中,与安慰剂相比,给予纤维蛋白原浓缩物未导致术中失血量出现显著差异。
研究设计与样本
- 随机、安慰剂对照、双盲临床试验,在荷兰Isala Zwolle开展,时间范围为2011年2月至2015年1月。
- 纳入择期高危心脏手术且术中出血(5分钟内从胸腔吸引血液体积60至250 mL)的患者,随机接受纤维蛋白原浓缩物(n=60)或安慰剂(n=60)。
- 干预为静脉单剂给予纤维蛋白原浓缩物或安慰剂,目标使输注后血浆纤维蛋白原水平达2.5 g/L。
- 共120例患者纳入研究,平均年龄71岁(SD 10),女性37例(31%),联合冠状动脉旁路移植术与瓣膜修复或置换术占手术的72%,平均体外循环时间200分钟(SD 83)。
主要发现
- 主要结局术中失血量:纤维蛋白原组中位数50 mL(四分位距29-100 mL),对照组70 mL(四分位距33-145 mL),P=0.19,绝对差异20 mL(95%CI -13至35 mL)。
- 卒中或短暂性脑缺血发作共6例,其中纤维蛋白原组4例。
- 心肌梗死共4例,其中纤维蛋白原组3例。
- 死亡共2例,均在纤维蛋白原组。
- 肾功能不全或衰竭共5例,其中纤维蛋白原组3例;再次开胸共9例,其中纤维蛋白原组4例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Fibrinogen concentrate might partly restore coagulation defects and reduce intraoperative bleeding. OBJECTIVE: To determine whether fibrinogen concentrate infusion dosed to achieve a plasma fibrinogen level of 2.5 g/L in high-risk cardiac surgery patients with intraoperative bleeding reduces intraoperative blood loss. DESIGN, SETTING, AND PARTICIPANTS: A randomized, placebo-controlled, double-blind clinical trial conducted in Isala Zwolle, the Netherlands (February 2011-January 2015), involving patients undergoing elective, high-risk cardiac surgery (ie, combined coronary artery bypass graft [CABG] surgery and valve repair or replacement surgery, the replacement of multiple valves, aortic root reconstruction, or reconstruction of the ascending aorta or aortic arch) with intraoperative bleeding (blood volume between 60 and 250 mL suctioned from the thoracic cavity in a period of 5 minutes) were randomized to receive either fibrinogen concentrate or placebo. INTERVENTIONS: Intravenous, single-dose administration of fibrinogen concentrate (n = 60) or placebo (n = 60), targeted to achieve a postinfusion plasma fibrinogen level of 2.5 g/L. MAIN OUTCOMES AND MEASURES: The primary outcome was blood loss in milliliters between intervention (ie, after removal of cardiopulmonary bypass) and closure of chest. Safety variables (within 30 days) included: in-hospital mortality, myocardial infarction, cerebrovascular accident or transient ischemic attack, renal insufficiency or failure, venous thromboembolism, pulmonary embolism, and operative complications. RESULTS: Among 120 patients (mean age; 71 [SD, 10] years, 37 women [31%]) included in the study, combined CABG and valve repair or replacement surgery comprised 72% of procedures and had a mean (SD) cardiopulmonary bypass time of 200 minutes (83) minutes. For the primary outcome, median blood loss in the fibrinogen group was 50 mL (interquartile range [IQR], 29-100 mL) compared with 70 mL (IQR, 33-145 mL) in the control group (P = .19), the absolute difference 20 mL (95% CI, -13 to 35 mL). There were 6 cases of stroke or transient ischemic attack (4 in the fibrinogen group); 4 myocardial infarctions (3 in the fibrinogen group); 2 deaths (both in the fibrinogen group); 5 cases with renal insufficiency or failure (3 in the fibrinogen group); and 9 cases with reoperative thoracotomy (4 in the fibrinogen group). CONCLUSIONS AND RELEVANCE: Among patients with intraoperative bleeding during high-risk cardiac surgery, administration of fibrinogen concentrate, compared with placebo, resulted in no significant difference in the amount of intraoperative blood loss. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01124981 and EudraCT No: 2009-018086-12.
引用
- Bilecen S, de Groot JA, Kalkman CJ, et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial. JAMA. 2017. PMID: 28241354. doi:10.1001/jama.2016.21037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。